CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  New England Journal of Medicine

• Publication date

  2016-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1506597PMID 26789870PMCID PMC4784450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

  2015cited by this paper
• Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy.

  2014cited by this paper
• Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

  2013cited by this paper
• Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

  2013cited by this paper
• Demonstration of CDX2 is Highly Antibody Dependant

  2012cited by this paper
• A Seven-Gene Signature Aggregates a Subgroup of Stage II Colon Cancers with Stage III

  2012cited by this paper
• Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature

  2012cited by this paper
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  2012cited by this paper
• Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer?

  2011cited by this paper
• Single-cell dissection of transcriptional heterogeneity in human colon tumors

  2011cited by this paper
• The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse.

  2011cited by this paper
• Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

  2011cited by this paper
• Ongoing challenge of stage II colon cancer.

  2011cited by this paper
• Molecular profiles and clinical outcome of stage UICC II colon cancer patients

  2011cited by this paper
• Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.

  2010cited by this paper
• The role of Cdx genes in the gut and in axial development.

  2010cited by this paper
• Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract.

  2010cited by this paper
• Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer

  2010cited by this paper
• Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis

  2010cited by this paper
• Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

  2010cited by this paper
• Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer

  2009cited by this paper
• Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer

  2009cited by this paper
• Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status

  2008cited by this paper
• Boolean implication networks derived from large scale, whole genome microarray datasets

  2008cited by this paper
• Extracting binary signals from microarray time-course data

  2007cited by this paper
• The prognostic role of a gene signature from tumorigenic breast-cancer cells.

  2007cited by this paper
• Phenotypic characterization of human colorectal cancer stem cells

  2007cited by this paper
• Stage II colon cancer prognosis prediction by tumor gene expression profiling.

  2006cited by this paper
• [Systemic therapy for colorectal cancer].

  2005cited by this paper
• Systemic therapy for colorectal cancer.

  2005cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

  2004cited by this paper
• CDX-2, a New Marker for Adenocarcinoma of Gastrointestinal Origin

  2004cited by this paper
• Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

  2004cited by this paper
• The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas

  2004cited by this paper
• ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival

  2004cited by this paper
• CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas

  2003cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  2001cited by this paper
• Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon.

  2001cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• American Joint Committee on Cancer prognostic factors consensus conference

  2000cited by this paper
• Homeosis and intestinal tumours in Cdx2 mutant mice

  1997cited by this paper

• CDX2 Expression and Fluoropyrimidine Response in Rare Non-GI Tumors: A Three-Case Series.

  2026cites this paper
• Explainable artificial intelligence with Boolean rule-aware predictions in ridge regression models

  2026cites this paper
• Mechanisms of the Antiproliferative Effects of SIRT6 Inhibition in Melanoma: A Multi-Omics Analysis.

  2026cites this paper
• High Grade Colorectal Adenocarcinomas with SMAD4 Deficiency.

  2026cites this paper
• Research progress of colorectal cancer in genomic and transcriptomic at multi-level

  2025cites this paper
• Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East.

  2025cites this paper
• Low CDX2 expression and its clinicopathological associations in colorectal adenocarcinoma: prognostic insights from a retrospective cross-sectional study in Vietnam

  2025influential citation
• Elevated MS4A12 expression is indicative of resistance to concurrent chemoradiotherapy and inferior survival in patients with rectal cancer

  2025influential citation
• Механизмы резистентности к иммунотерапии при MSI фенотипе

  2025cites this paper
• Evaluation of CDX2 Protein Expression Pattern in Colorectal Adenocarcinoma and Exploring Its Association With Prognostic Parameters

  2025cites this paper
• A comprehensive analysis of transcription factors identified TCF3 as a prognostic target for glioma

  2025cites this paper
• Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer

  2025cites this paper
• CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

  2025cites this paper
• KnowYourCG: Facilitating base-level sparse methylome interpretation

  2025cites this paper
• Distinct colitis-associated macrophages drive NOD2-dependent bacterial sensing and gut homeostasis

  2025cites this paper
• Decoding Colon Cancer Heterogeneity Through Integrated miRNA–Gene Network Analysis

  2025cites this paper
• Distinct Colitis-Associated Macrophages Drive NOD2-Dependent Bacterial Sensing and Gut Homeostasis

  2025cites this paper
• ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors

  2025cites this paper
• The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine

  2025cites this paper
• CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer

  2025cites this paper
• Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype

  2025cites this paper
• CANDiT: A machine learning framework for differentiation therapy in colorectal cancer

  2025cites this paper
• Tissue and cellular spatiotemporal dynamics in colon aging.

  2025cites this paper
• Identification of novel diagnostic biomarkers in stages I-IV colorectal cancer

  2025cites this paper
• Caudal-Type Homeobox Transcription Factor 2 is a Favorable Prognostic Indicator in Stage II and III Gastric Cancer Following Curative Surgery

  2024cites this paper
• Autofluorescent Cancer Stem Cells: Potential Biomarker to Predict Recurrence in Resected Colorectal Tumors

  2024cites this paper
• F.O.R.W.A.R.D: A Data-Driven Framework for Network-Based Target Prioritization in Drug Discovery

  2024cites this paper
• [Quantification of CDX2 using H-Score and its prognostic value in colon cancer].

  2024cites this paper
• Progressive plasticity during colorectal cancer metastasis

  2024cites this paper
• Knockdown of CDX2 Induces microRNA-221 Up-regulation in Human Colon Cancer Cells

  2024cites this paper
• The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

  2024cites this paper
• Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).

  2024cites this paper
• CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways

  2024influential citation
• Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management

  2024cites this paper
• Prognostic Biomarkers for Hepatocellular Carcinoma Based on Serine and Glycine Metabolism-related Genes

  2024cites this paper
• ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer

  2024cites this paper
• Tissue-location-specific transcription programs drive tumor dependencies in colon cancer

  2024cites this paper
• Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.

  2024cites this paper
• Computational single-cell methods for predicting cancer risk.

  2024cites this paper
• C1QA is an invariant biomarker for tissue macrophages

  2024cites this paper
• Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients.

  2024cites this paper
• Molecular Biology of Cancer—Interplay of Malignant Cells with Emerging Therapies

  2024cites this paper
• Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies.

  2024cites this paper
• Detecting Boolean Asymmetric Relationships with a Loop Counting Technique and its Implications for Analyzing Heterogeneity within Gene Expression Datasets

  2024cites this paper
• The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers

  2024cites this paper
• Loss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer

  2024influential citation
• Identification of a novel signature related to the immune landscape and prognosis for human colonic adenocarcinoma based on lncRNA pairs

  2024cites this paper
• The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer

  2024cites this paper
• Tissue and cellular spatiotemporal dynamics in colon aging

  2024cites this paper
• Evaluation of the Immunohistochemical Scoring System of CDX2 Expression as a Prognostic Biomarker in Colon Cancer

  2024influential citation
• Oncogenic ALK fusion in rare subtype of small intestine metastasis from occult lung cancer

  2024cites this paper
• Forkhead box protein D2 suppresses colorectal cancer by reprogramming enhancer interactions

  2023cites this paper
• High-fat diet plus HNF1A variant promotes polyps by activating β-catenin in early-onset colorectal cancer

  2023cites this paper
• Molecular profiling of colorectal cancer in a genetically admixed Hispanic population

  2023cites this paper
• Regularized survival learning and cross-database analysis enabled identification of colorectal cancer prognosis-related immune genes

  2023cites this paper
• A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer

  2023cites this paper
• CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

  2023cites this paper
• Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights.

  2023cites this paper
• Lower Expression of CFTR Is Associated with Higher Mortality in a Meta-Analysis of Individuals with Colorectal Cancer

  2023cites this paper
• PROX1 induction by autolysosomal activity stabilizes persister-like state of colon cancer via feedback repression of the NOX1-mTORC1 pathway.

  2023cites this paper
• Growth signaling autonomy in circulating tumor cells aids metastatic seeding

  2023cites this paper
• Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study

  2023cites this paper
• A cellular senescence-related genes model allows for prognosis and treatment stratification of hepatocellular carcinoma: A bioinformatics analysis and experimental verification

  2023cites this paper
• CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy

  2023cites this paper
• Identification of a novel gene signature for neuroblastoma differentiation using a Boolean implication network

  2023cites this paper
• Decoding the basis of histological variation in human cancer

  2023cites this paper
• Spatial characterization and stratification of colorectal adenomas by deep visual proteomics

  2023cites this paper
• Axillary cutaneous metastasis of colon cancer with microsatellite instability-high and BRAF V600E mutation treated with curative-intent surgery: a case report

  2023cites this paper
• Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance

  2023cites this paper
• The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.

  2023influential citation
• Genetic and immune landscape evolution in MMR‐deficient colorectal cancer

  2023cites this paper
• PHLPP2: A Prognostic Biomarker in Adenocarcinoma of the Rectum

  2023cites this paper
• CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer

  2023cites this paper
• Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

  2023cites this paper
• Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer

  2023cites this paper
• The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

  2023influential citation
• Progressive plasticity during colorectal cancer metastasis

  2023cites this paper
• Machine Learning–Guided Differentiation Therapy Targets Cancer Stem Cells in Colorectal Cancers

  2023cites this paper
• Feasibility of Inferring Spatial Transcriptomics from Single-Cell Histological Patterns for Studying Colon Cancer Tumor Heterogeneity

  2023cites this paper
• PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

  2023cites this paper
• Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.

  2023cites this paper
• Macrophage states: there's a method in the madness.

  2023cites this paper
• Prise en charge du cancer du côlon après résection curative

  2023cites this paper
• Novel inherited CDX2 variant segregating in a family with diverse congenital malformations of the genitourinary system

  2023cites this paper
• The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection

  2023cites this paper
• Primary adenocarcinoma of colon: A clinicopathological study with the prevalence and correlation of CDX2 biomarker expression - A tertiary care center experience.

  2023cites this paper
• An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer

  2022cites this paper
• Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20

  2022cites this paper
• Pattern of Expression of CDX2 in Colorectal Cancer and its Role in Prognosis: An Ambispective Observational Study

  2022cites this paper
• Cell2Grid: an efficient, spatial, and convolutional neural network-ready representation of cell segmentation data

  2022cites this paper
• Identification of Spatial Proteomic Signatures of Colon Tumor Metastasis: A Digital Spatial Profiling Approach

  2022cites this paper
• A Rare Case of Cardiac Metastasis from Colon Cancer

  2022influential citation
• Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens

  2022cites this paper
• Novel Diagnostic Biomarkers in Colorectal Cancer

  2022cites this paper
• CDX2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in Colorectal Cancer

  2022influential citation
• Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling

  2022cites this paper
• Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery

  2022cites this paper
• Effect of a combination of oxaliplatin and fluoropyrimidine derivative molecule S-1 on expression levels of IL-9 and CysLTR-1 in a rat model of colon cancer

  2022cites this paper
• Hidden patterns of gene expression provide prognostic insight for colorectal cancer

  2022cites this paper
• Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement

  2022cites this paper